of infectious complications was 18% (95%CI 4-37%), thromboembolic complications 5% (95%CI 0-15%) and mechanical failure 7% (95%CI 3-12%). Only two studies reported on rates of superficial thrombophlebitis and analysis was unable to be performed. There was significant statistical heterogeneity between studies, for all outcomes except mechanical failure (I 2
OBJECTIVE: Approximately 20-50% of venous thromboembolism (VTE) in pregnancy and postpartum are ultimately identified to have an inherited thrombophilia. As VTE remains one of the leading yet potentially preventable causes of severe maternal morbidity and mortality in the US, we employed a decision analytic model to evaluate if universal screening for thrombophilia would result in increased detection and decreased mortality in our obstetric population as a strategy to reduce VTE related maternal morbidity and mortality. STUDY DESIGN: A decision analytic model was used to compare three screening strategies: no screening, individual inherited thrombophilia screening (Factor V Leiden, Prothrombin gene mutation and Antithrombin III) or a comprehensive panel screening (a single screening panel designed to identify the above 3 thrombophilias). Probability estimates for relevant events and outcomes were obtained from the literature and utilized data specific to the obstetric patient population when available (Table 1 ). For our base case analysis we applied our model to 3 million women to represent the number of new pregnancies annually and chose a VTE probability of 0.5/1000 pregnancies in unscreened, untreated women based on the most recently published American College of Obstetricians and Gynecologists clinical practice guidelines on thromboembolism and inherited thrombophilias. One-way sensitivity analyses were performed. RESULTS: After applying our model to 3 million women, universal screening using a comprehensive screening panel was the strategy that most significantly reduced the occurrence of VTE. The model was most impacted by the probability of Factor V Leiden heterozygosity in the population. Even with the most prevalent thrombophilias, the number need to screen to prevent a single VTE was 3,610 and 95,238 to prevent a maternal mortality from a VTE secondary to an undiagnosed thrombophilia (Table 2) . One-way sensitivity analyses demonstrated that even with a reduction in the frequency of VTE with thromboprophylaxis the number needed to screen was still unacceptably high. CONCLUSION: VTE is a leading cause of severe maternal morbidity and mortality in the United States and inherited thrombophilias account for 20-50% of VTE episodes in pregnancy. A universal screening strategy does reduce the number of VTE episodes and resultant maternal deaths in our model, however, the number needed to screen and treat to prevent a VTE or maternal death remains extremely high.
833 Heart of the matter: preliminary-analysis of the california maternal quality care collaborative cardiovascular disease toolkit. 
OBJECTIVE:
The California Maternal Quality Care Collaborative (CMQCC) recently published a cardiovascular disease (CVD) toolkit for identification of CVD in pregnant/postpartum women. We aim to obtain a baseline screen positive rate and delineate the true positives among women who screened positive. STUDY DESIGN: This is a cross-sectional study from a convenience sample of patients presenting for pregnancy care between April 2018 and July 2018 at University of California, Irvine. Subjects were screened at least once, either during pregnancy or postpartum period. Patients screened positive if they exhibited: 'Red Flags' , had history of prior CVD, or a combination of moderate risk factors (Figure 1) . Patients who screened positive underwent further testing. The primary outcome was the screen positive rate (Table 1) . Secondary outcomes were the "true positive" rate and the strength of each of the moderate factors in predicting CVD. Univariate logistic regression was used to analyze data. RESULTS: 319 women were screened (228 antepartum/intrapartum; 73 postpartum). Only 2.5% of the cohort was African American, 53% was Hispanic, with a large remainder being Caucasian. Overall, 17 (5.3%) patients screened positive and 4 (1.3%) were identified as "true positives" upon further evaluation, i.e. evidence of cardiac disease. Red flags and prior CVD history constituted 9 of 17 screen positive cases; 2 of 4 "true positive" cases were identified from these factors. No patients screened positive by physical exam criteria. Moderate risk factors identified 11 of 17 screen positive cases; 3 of 4 true positives would have been identified based on moderate factors. Table 1 illustrates predictive potential of the moderate factors for a screen positive result. CONCLUSION: CVD is the leading cause of maternal mortality 1 , and 25% of these are preventable.
2-4 We report preliminary findings of the baseline CVD screen positive rate and the true positive rate in an obstetrical population at a tertiary care center. Additionally, we identified the most relevant moderate factors, which may allow modification of the toolkit. Limitations include small sample size and underrepresentation of African Americans. These data may be utilized to design a larger multicenter investigation to validate the CVD algorithm.
834 Impact of maternal body-mass-index on brachial plexus injury: a retrospective cohort study OBJECTIVE: We aimed to characterize the impact of maternal prepregnancy body-mass-index (BMI) on the risk of brachial plexus injuries in deliveries unaffected by shoulder dystocia. STUDY DESIGN: This is a retrospective cohort study of nulliparous and multiparous women with term deliveries unaffected by shoulder
